Ariosa Diagnostics has announced the availability of Harmony prenatal test in the US and Canada through Laboratory Corporation of America Holdings (LabCorp) and Integrated Genetics.
The non-invasive test uses a directed approach to analyze cell-free DNA (cfDNA) in maternal blood to detect common fetal trisomies, such as Trisomy 21 (associated with Down syndrome).
Ariosa chief executive officer Ken Song said with enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies.
"The Harmony Prenatal Test is an affordable, high-quality test that provides a new choice for women," Song added
"Together with LabCorp, we are committed to ensuring that the latest advances in prenatal testing are accessible to all healthcare providers and women."
The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.
